VIVUS

VIVUS, Inc. is a drug-development company dedicated to the development and commercialization of next-generation therapeutic products addressing obesity, diabetes, sleep apnea and sexual health.

- Postmarketing requirement fulfilled based on data demonstrating QYSMIA® reduces blood pressure - CAMPBELL, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- VIVUS announced today that the U.S. Food and Drug Administration has removed the requirement for a cardiovascular outcome trial for its weight-management medication QSYMIA (phentermine and topiramate extended release capsules) CIV.

VIVUS Shares Significant Regulatory Update on QSYMIA®

CAMPBELL, Calif., Dec. 11, 2020 (GLOBE NEWSWIRE) -- VIVUS, Inc. (the “Company”), a biopharmaceutical company, today announced that it has received approval from the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”) on its Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (the “Plan”).

VIVUS Receives Court Approval of Joint Chapter 11 Plan of Reorganization

CAMPBELL, Calif., Nov. 13, 2020 (GLOBE NEWSWIRE) -- On November 10, 2020, VIVUS, Inc. (the “Company”), a biopharmaceutical company, filed the Second Amended Joint Prepackaged Chapter 11 Plan of Reorganization of VIVUS, Inc. and Its Affiliated Debtors [Docket No. 339] (as may be amended, modified, or supplemented from time to time, the “Plan”) with the United States Bankruptcy Court for the District of Delaware (the “Bankruptcy Court”). As set forth in a letter filed with the Bankruptcy Court (the “Equity Support Letter”), the Plan has the full support of the official committee of equity security holders appointed in the Company's chapter 11 case (the “Equity Committee”) and incorporates the terms and conditions of the plan support agreement filed with the Bankruptcy Court on November 5, 2020 [Docket No. 329] and available, along with all other documents filed with the Bankruptcy Court, on the electronic case filing docket and free of charge on the website maintained by the Company's voting agent, Bankruptcy Management Solutions, Inc. d/b/a Stretto (the “Voting Agent”) at https://cases.stretto.com/vivus/. This press release is qualified in its entirety by the Plan and the Plan Supplement (as defined herein), which govern in the event of any inconsistency. Unless otherwise indicated, all capitalized terms used herein have the same meaning assigned in the Plan.

VIVUS Seeks Bankruptcy Court Approval of Second Amended Joint Chapter 11 Plan of Reorganization and Existing Stock Record Date

CAMPBELL, Calif., July  07, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has completed the solicitation of an in-court prepackaged plan of reorganization, under which IEH Biopharma LLC (“IEH”) will take 100% ownership of VIVUS (the “Prepackaged Plan”), ahead of its July 7, 2020 chapter 11 filing.  The Company solicited IEH―as the only holder of claims in classes entitled to vote on the Prepackaged Plan―and has received IEH’s ballots voting in favor of the Prepackaged Plan in accordance with the amended and restated Restructuring Support Agreement executed by the Company and IEH on July 6, 2020. The Company believes that the Prepackaged Plan satisfies all requirements necessary for confirmation by the Court.  The Company will request a combined disclosure statement and confirmation hearing for August 17, 2020, subject to the Court’s availability.  Upon confirmation of the Prepackaged Plan, the Company intends to consummate the restructuring transactions shortly thereafter. 

VIVUS Completes Solicitation for In-Court Reorganization Plan to Become a Wholly Owned Subsidiary of IEH Biopharma LLC

CAMPBELL, Calif., June  02, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has updated its agreement regarding its corporate debt with Icahn Enterprises Holdings L.P. (dba IEH Biopharma LLC), which holds a principal amount of approximately $170.2 million of the Company’s Convertible Senior Notes.

VIVUS Announces Updated Agreement with Icahn Enterprises Holdings L.P.

VIVUS, Inc's (VVUS) CEO John Amos on Q1 2020 Results - Earnings Call Transcript

CAMPBELL, Calif., May  01, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced an agreement regarding its corporate debt with IEH Biopharma LLC, which holds a principal amount of  approximately $170.1 million of the Company’s Convertible Senior Notes with a maturity date of May 1, 2020. The Company does not currently have the ability to pay the principal amount of the Convertible Senior Notes held by IEH Biopharma. Under the terms of the agreement, the Company will pay IEH Biopharma $3.8 million in accrued and unpaid interest on the Convertible Senior Notes and IEH Biopharma will grant the Company a 30-day grace period (if not terminated sooner pursuant to the terms of the agreement), beginning today, for payment of the principal amount of the Convertible Senior Notes during which the two parties will work exclusively to attempt to restructure the outstanding principal amount of the Convertible Senior Notes. As part of the agreement, VIVUS will settle or otherwise satisfy the remaining $11.3 million in principal and $253,373 in accrued and unpaid interest held by other holders.

VIVUS Announces Agreement with IEH Biopharma LLC Granting the Company a 30-Day Grace Period to Restructure its Corporate Debt

VIVUS Finding Support After Launch Of Its Remote Health Platform

CAMPBELL, Calif., April  03, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced the completion of its previously announced registered direct offering of 7,218,750 shares of the Company’s common stock at a purchase price of $1.60 per share for gross proceeds of $11.55 million, before deducting the placement agent’s fees and other offering expenses payable by the Company.

VIVUS Announces Closing of $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Vivus (NASDAQ: VVUS) shares were trading lower on Wednesday, after the company priced its 7.22 million share common stock offering at $1.60 per share.

Why Vivus Is Trading Lower Today

CAMPBELL, Calif., April  01, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS; the “Company”), a biopharmaceutical company, today announced that it has entered into definitive agreements with several institutional and accredited investors for the purchase and sale of 7,218,750 shares of the Company’s common stock, at a purchase price of $1.60 per share, in a registered direct offering priced at-the-market under Nasdaq rules. The closing of the offering is expected to occur on or about April 3, 2020, subject to the satisfaction of customary closing conditions.

VIVUS Announces $11.55 Million Registered Direct Offering Priced At-the-Market under Nasdaq Rules

Shares of biopharma company VIVUS, Inc. (NASDAQ: VVUS) are skyrocketing following an announcement concerning launch plans for telemedicine services.

Vivus Shares Rally On Accelerated Telemedicine Launch

Vivus Inc. (NASDAQ: VVUS) shares absolutely exploded on Tuesday after the company announced that it was accelerating the launch of the telemedicine and remote monitoring modules of the Vivus Health Platform.

Will Vivus Be the Next Big Name in Telemedicine?

Virtual office visits and smart health devices available through the VIVUS Health Platform give physicians new tools for optimizing patient care and protecting the health of those at increased risk for COVID-19

VIVUS Accelerates the Launch of Telemedicine and Remote Monitoring Modules to Facilitate Effective Patient Care During “Social Distancing”

VIVUS, Inc. (VVUS) CEO John Amos on Q4 2019 Results - Earnings Call Transcript

VIVUS, Inc. (VVUS) CEO VIVUS, Inc.

- Company to host conference call today at 4:30pm ET -

VIVUS Reports Fourth Quarter and Full Year 2019 Financial Results

-Post-marketing study designed to evaluate Qsymia as an approach to weight management in a growing patient population with significant unmet medical need-

VIVUS Completes Enrollment in Phase 4 Safety and Efficacy Study of Qsymia® in Adolescents

- VIVUS to Receive Milestone Payment from Alvogen; Significant Worldwide Growth Potential for Qsymia -

VIVUS Announces Commercial Launch of Qsymia® in the Republic of Korea Establishing New Royalty Revenue Stream

Vivus Inc. (NASDAQ: VVUS) shares jumped on Wednesday after the company announced a crucial approval by the U.S.

Why This FDA Approval Is a Big Win for Vivus

CAMPBELL, Calif., Feb.  05, 2020  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (“VIVUS”), a biopharmaceutical company, today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental New Drug Application (sNDA) for an improved formulation of PANCREAZE® (pancrelipase) Delayed Release Capsules that extends the shelf life to 36 months across all PANCREAZE dosages. VIVUS worked closely with Nordmark Arzneimittel GmbH & Co. KG, its manufacturing partner for PANCREAZE, on the FDA approval pursuant to the terms of the  amended contract manufacturing agreement announced in  June 2019 . PANCREAZE is indicated for the treatment of exocrine pancreatic insufficiency (EPI) due to cystic fibrosis or other conditions.

VIVUS Receives U.S. Food and Drug Administration Approval for Improved Formulation of PANCREAZE® with a 36-Month Shelf Life

-Data published in Journal of General Internal Medicine show that patients using Qsymia and other weight loss tools, lost at least 5% of body weight loss compared with those not using Qsymia-

New Data Further Demonstrate Effectiveness of VIVUS’ Qsymia as a Weight Management Tool

CAMPBELL, Calif., Dec.  31, 2019  (GLOBE NEWSWIRE) -- VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a biopharmaceutical company, today announced that on December 30, 2019 its board of directors adopted a new stockholder rights plan to replace the Company’s stockholder rights plan that expired in accordance with its terms on November 9, 2019.

VIVUS Adopts Stockholder Rights Plan

-Data published in Diabetes, Obesity and Metabolism demonstrate that Qsymia provides statistically significant weight loss compared with placebo over an 8 week period, provide basis for ongoing 56 week phase 4 study in obese adolescents-

VIVUS Announces New Data Supporting the Safety and Efficacy of Qsymia® in Adolescents with Obesity

Shares of Vivus Inc. rose 9% in morning trading after the drugmaker said its weight-loss drug Qsymia can reduce binging frequency for patients with binge-eating disorder or bulimia nervosa.

News for VIVUS Stock (VVUS)